<DOC>
	<DOC>NCT02220738</DOC>
	<brief_summary>This study is designed to evaluate the safety, tolerability and pharmacokinetics of multiple doses of ABT-957 in subjects with mild to moderate Alzheimer's disease.</brief_summary>
	<brief_title>Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable Alzheimer's disease (AD); Has a MiniMental State Examination total score of 16 to 26; Has a Modified Hachinski Ischemia Scale score of â‰¤ 4; Is taking a stable dose of donepezil, galantamine or rivastigmine for at least 30 days; Has had a computerized tomography or magnetic resonance imaging. The scan must not show evidence for an alternative etiology for dementia; With the exception of a diagnosis of mildtomoderate AD and the presence of stable medical conditions, is in general good health. Positive screen for drugs of abuse, alcohol or cotinine; Females must not have positive results for pregnancy; Focal neurological signs on examination; Has a clinically significant abnormal value, in serum chemistry, hematology or urinalysis; History of any significant neurologic disease other than AD; History of head trauma, motor vehicle accident, concussion.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Alzheimer's Disease</keyword>
</DOC>